Second pass at: Pharmacy supply in the UK and the questions you will be asked

Second pass at: Pharmacy supply in the UK and the questions you will be asked Writing it up because I had to work it out twice and would rather nobody else did.

A coverage question with the paperwork detail included, since that is what determines the answer.

Denial received, with a stated reason. My reading of the reason is that it tells me exactly what to submit next, which is the useful thing about a well-written denial.

Before I spend a week on it: is my reading of the stated criterion correct, and is there a documented precedent for this specific ground?

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Worth separating two things that post #12 runs together.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

On post #16 — agreed on the reasoning, with one qualification.

Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.

Coming back to post #25, because the follow-up matters more than the original answer.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

post #36 answers the question as asked. The question underneath it is different.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

Worth separating two things that post #48 runs together.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.